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Abstract: Inducers of ferroptosis such as the glutathione depleting agent Erastin and the GPX4
inhibitor Rsl-3 are being actively explored as potential therapeutics in various cancers, but the factors
that determine their sensitivity are poorly understood. Here, we show that expression levels of both
subunits of the cystine/glutamate antiporter xCT determine the expression of GPX4 in breast cancer,
and that upregulation of the xCT/selenocysteine biosynthesis/GPX4 production axis paradoxically
renders the cancer cells more sensitive to certain types of ferroptotic stimuli. We find that GPX4
is strongly upregulated in a subset of breast cancer tissues compared to matched normal samples,
and that this is tightly correlated with the increased expression of the xCT subunits SLC7A11 and
SLC3A2. Erastin depletes levels of the antioxidant selenoproteins GPX4 and GPX1 in breast cancer
cells by inhibiting xCT-dependent extracellular reduction which is required for selenium uptake
and selenocysteine biosynthesis. Unexpectedly, while breast cancer cells are resistant compared to
nontransformed cells against oxidative stress inducing drugs, at the same time they are hypersensitive
to lipid peroxidation and ferroptosis induced by Erastin or Rsl-3, indicating that they are ‘addicted’ to
the xCT/GPX4 axis. Our findings provide a strategic basis for targeting the anti-ferroptotic machinery
of breast cancer cells depending on their xCT status, which can be further explored.
Keywords: ferroptosis; GPX4; Erastin; Rsl-3; breast cancer; selenium; lipid peroxidation
1. Introduction
Ferroptosis is a form of cell death that involves an iron-dependent accumulation of
lipid peroxides. Several cellular components have emerged as playing key roles in the
regulation of ferroptosis. The cystine-glutamate antiporter xCT which is composed of the
subunits SLC7A11 and SLC3A2, plays a protective role against ferroptosis by allowing
the import of cystine, which is a rate-limiting step in the biosynthesis of the antioxidant
molecule glutathione [1]. The enzyme glutathione peroxidase 4 (GPX4) utilizes glutathione
as a substrate for reduction, and the activity of GPX4 in reducing lipid peroxidation has
been shown to be a key step in the prevention of ferroptosis [2].
GPX4 is a selenoprotein, with a selenocysteine residue in its active site, and thus it
requires selenocysteine biosynthesis for its expression and activity [3,4]. The selenocysteine
biosynthesis pathway incorporates selenium, such as in the dietary form selenite, to
produce selenocysteinyl-tRNA. The antioxidant function of selenium as a nutrient is
mediated through selenoproteins such glutathione peroxidases and thioredoxins, including
GPX4, thus implicating selenium in ferroptosis as well [5,6]. Furthermore, it was found
that elevated SLC7A11 expression in cancer cells drives selenocysteine biosynthesis by
promoting selenite reduction and uptake as an early step in selenocysteine biosynthesis [4].
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Thus, SLC7A11 allows both the production of glutathione, and the production of the
enzyme (GPX4) that utilizes it.
Breast cancer, along with lung cancer, is the most common cancer in the world [7].
While successful treatment paradigms have emerged for breast cancers expressing estro-
gen, progesterone, or Her2 receptors, triple negative breast cancers (TNBCs) that do not
express any of these receptors are refractory to conventional chemotherapeutics and have a
markedly poor prognosis [8]. Well-established chemical inducers of ferroptosis, such as
the GPX4 inhibitor Rsl-3 and the xCT inhibitor Erastin, and their derivatives, are currently
being explored as potential therapeutics for breast cancer therapy and have been shown to
exert toxicity in these and other cancer cells [9]. On the other hand, what determines the
sensitivity and resistance of cells to these compounds is a critical issue that must be further
explored to develop ferroptotic induction as a valid therapeutic strategy for cancer.
Here, we examined the expression and functional importance of ferroptotic machinery
between transformed and nontransformed cells. We observe that expression of the xCT
components SLC7A11 and SLC3A2 are elevated in a subset of patient breast tumor tissues
compared to normal breast tissue, and that their coordinated expression tightly correlates
with GPX4 expression. We find that the xCT inhibitor Erastin disrupts expression of antiox-
idant selenoproteins by impairing xCT mediated extracellular reduction, which is required
for uptake of selenite and selenocysteine biosynthesis, indicating that modulation of se-
lenoprotein expression is a potentially important and previously unrecognized function of
Erastin. In a panel of breast cancer and nontransformed immortalized breast epithelial cell
lines, we find the breast cancer lines to be resistant to hydrogen peroxide, consistent with
increased GPX4 function. Paradoxically, the breast lines are at the same time hypersensitive
to the Erastin and Rsl-3 indicating that breast cancer cells are addicted to the xCT/GPX4
axis to prevent ferroptosis. Our findings indicate a therapeutic window and mechanism
for compounds targeting the antiferroptotic machinery of breast cancer cells.
2. Materials and Methods
All reagents used in this paper are listed in Supplementary Table S1.
2.1. Cell Lines and Cell Culture
All cell lines were cultured in a humidified incubator at 37 ◦C under 5% CO2. The cell
line information used in this paper is provided in Supplementary Table S2.
2.2. Western Blot Analysis
Cells were washed with cold PBS and lysed in RIPA lysis buffer with protease in-
hibitor (Sigma Aldrich, St. Louis, MO, USA). After 20 min incubation on ice, lysates were
centrifuged at 12,000× g at 4 ◦C for 10 min to collect supernatant. Protein concentration of
each samples was determined by Bradford assay. Typically, 15–25 µg of total protein were
denatured in 6× Lamelli buffer (Boston bioproducts, Boston, MA, USA), loaded per lane
on SDS-PAGE gel (Biorad, Hercules, CA, USA), and analyzed by standard immunoblotting.
The target proteins were detected by ECL, Pico or diluted Femto substrate (Thermo Fisher
Scientific, Waltham, MA, USA).
2.3. Cell Viability Assay
The effect of GPX4 inhibition is affected by cell confluency (31341276). Thus, all
viability assays were performed with consistently regarding cell seeding number and time
points. For testing toxicity of hydrogen peroxide, Erastin and Rsl-3 in cell lines, 1500 cells
were plated in a 96 well plate. Next day, cells were treated with the drugs. Cell viability
was measured by CellTiter-Glo Luminescent Assay (Promega, Madison, WI, USA).
2.4. Conditioned Media Thiol Quantification (Ellman’s Test)
10,000 cells were plated per well of a 96 well plate. The next day, the media was
changed to 100 µL fresh media containing vehicle or Erastin. After 12 h conditioning, the
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conditioned media were collected and directly mixed with 50 µL of 10 mM DTNB (5,5′-
dithiobis-(2-nitrobenzoic acid)) dissolved in DMSO in another 96 well plate. Absorbance
at 450 nm was measured spectrophotometrically in 3 min (DTX880, Beckman Coulter,
Indianapolis, IN, USA). The blank value was subtracted as noise, and all values were
normalized to that of unconditioned media. The leftover cells in the 96 well plate were
subjected to the CellTier-Glo Luminescent Assay after adding fresh media. As phenol red
mask the changed color of DTNB, phenol red-free media was used for this assay.
2.5. Total Selenium Measurement by ICP-MS Analysis
3 million CAL120 and 4 million MDAMB231 cells were plated in 150 pi dish, and
media were changed with that containing vehicle, 12 µM selenite, or 12 µM Erastin the
next day. After 2 h of treatment, cells were harvested and washed three times with cold
PBS, and weighed. The cell pellets were treated with 500 µM 1:1 H2O2/HNO3 and stood
in a safety hood for 12 h at room temperature with periodic venting. Samples were then
sonicated for 1 h at 35 kHz and 40 ◦C with periodic venting. Contents of the Eppendorf
tubes were then transferred to a glass digestion tube with ASTM type I water (2 × 1 mL).
Tubes were sealed, heated at 140 ◦C for 2 h, then cooled and diluted to 5 mL with ASTM
type I water for selenium analysis.
Selenium measurements were carried out with an Agilent 7500A ICP-MS system which
had a standard concentric nebulizer, a Peltier-cooled and double-pass Scott-type spray chamber,
torch shield, and standard Nickel interface cones. Between each analytical sample, the probe
sample introduction system was rinsed with 10% nitric acid for 60 s to prevent carryover.
Calibration curves were made with standard solutions of Se (Ultra Scientific, Kingstown, RI,
USA) and QC samples using a multi-element standard (Environmental Express).
2.6. Detection of Lipid Peroxidation
Cells were collected by trypsinization and washed with HBSS. The cell pellets were
resuspended with 150 µL of 5 µM BODIPY™ 581/591 C11 lipid peroxidation sensor (Thermo
Fisher Scientific, Waltham, MA, USA) in HBSS and incubated at 37 ◦C. After 20 min incubation,
500 µL of HBSS was added to the stained cells and subjected to FACS analysis with BD LSR II
flow cytometer immediately. Briefly, SSC-A and FSC-A gating strategy was applied to remove
the cell debris. FSC-H and FSC-A subgating was performed to identify single cell population.
Around 10,000 cells gated as single were used for analysis. BD FACS Diva program and
FLOWJO10 were used for data collection and data analysis, respectively.
2.7. RNA Expression and Prognostic Value SLC7A11 and SLC3A2 in Normal and Tumor Tissues
Analyses of gene expression data in breast normal and cancer tissues, and disease
free survival and overall survival in patients with breast cancer were performed using
the web tool GEPIA [10]. Total numbers of samples for each analysis are not designated
by the user; instead the GEPIA web tool designates the high and low from the median
and provides the total numbers. Total numbers may differ between the different genes
(SLC7A11 vs. SLC3A2) due to some samples not meeting the GEPIA criteria for either high
or low designation for the given gene.
2.8. Processing of Human Breast Tissues
Human breast cancer samples and normal breast tissues were obtained with informed
consent from the University of Massachusetts Medical School Biorepository and Tissue
Bank using procedures which were conducted under an Institutional Review Board (IRB)-
approved protocol. After surgical removal, fresh tumor tissues or normal tissues were
immediately snap-frozen in liquid nitrogen and stored at −80 ◦C. Later, tissues were
homogenized in RIPA buffer with complete protease inhibitor cocktail, then centrifuged at
13,000× g at 4 ◦C for 10 min. Samples were normalized for protein content and western
blots were performed. Protein bands were quantified using Image J program. Scanned
films were inverted, and the intensity of each band was measured, and then the background
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value was subtracted. The intensity value of protein bands for each sample was normalized
to the intensity value for Actin or GAPDH proteins.
2.9. Quantification and Statistical Analysis
Results of the viability assay, comparison of protein expressions between normal
and cancer tissues, Ellman’s test and total selenium measurement were analyzed using
Student’s t test. Disease free survival and overall survival in patients with breast cancer
were compared between xCT high and low groups using the Kaplan–Meier method, and
significant differences in curves were assessed using the log-rank test. Values of p < 0.05
were considered statistically significant, and data marked with a one (*), two (**) or three
(***) asterisks indicate p values of <0.05, <0.01 and <0.001, respectively.
3. Results
3.1. Expression of xCT, an Initial Step of Selenocysteine Synthesis Pathway, Is Highly Upregulated
in Breast Cancer Tissues and Expression of GPX4 Is High in xCT Positivie Tumors
As xCT activity was shown to drive the expression of the selenoprotein GPX4 via the
selenocysteine biosynthesis pathway (Figure 1a, [4]), we examined the levels of SLC7A11,
SLC3A2, and GPX4 in breast normal and cancer tissues to confirm if this pathway is altered
in cancer tissues and if GPX4 expression is associated with the expression of xCT. First, we
analyzed normalized mRNA transcript levels of SLC7A11 and SLC3A2 from data from
The Cancer Genome Atlas (TCGA) compared with normal tissues from (GTEx), using the
web tool GEPIA [10], which demonstrated a trend towards increased mRNA levels which
was not significant (Figure 1b); similar non-significant trends for increase in both subunits
was observed in data mining across multiple cancer types (Supplementary Figure S1a).
When directly examining protein levels from patient-derived breast tumor samples and
normal breast tissues, we found that the expression levels of the xCT subunits, SLC7A11
and SLC3A2, were significantly upregulated in breast tumor tissues compared with normal
tissues (Figure 1c,d). xCT requires both these subunits [4], thus we tried to distinguish
between tissues that express only one or both of the subunits. Interestingly, there were
6 cancer tissues out of 14 that expressed significant levels of both SLC7A11 and SLC3A2,
which we designated xCT positive tissue (Figure 1e), while none of the normal breast
tissues was xCT positive (Figure 1c). Interestingly, when comparing expression across all
tumor samples versus all normal tissue samples, in contrast to SLC3A2 and SLC7A11, GPX4
was not significantly overexpressed in cancer tissues compared to normal tissues across the
set (Figure 1d). In contrast, when directly comparing the protein expression levels of GPX4
in xCT-positive tumors with their paired (i.e., from the same patient) normal breast tissue,
or comparing all xCT positive tumors tissues with all xCT-negative tumor tissues, we saw
statistically significant increases of GPX4 expression in the xCT positive group (Figure 1f).
Furthermore, analyses of TCGA data indicated that high expression of both subunits of xCT
was significantly associated with poor overall survival (Figure 1g) and disease-free survival
(Figure 1h) in patients with breast cancer. In contrast, expression of either SLC7A11 or
SLC3A2 alone did not have significant prognostic value (Supplementary Figure S2a,b).
These findings support the notion that xCT drives the expression of GPX4 [4], and that
the elevated expression of both SLC7A11 and SLC3A2 is a determinant for increased xCT
function as indicated by GPX4 expression—And is associated with poor prognosis in
breast cancer.
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. . r sti r ets the Selenium Uptake and Selenoprotein Expression Promoting Activity of xCT
Erastin is an established xCT inhibitor and inducer of ferroptosis, and is currently
being explored as a potential breast cance therapeutic agent. The ferroptos inducing
activity of Erastin nd other xCT inhibito compounds have been primarily attributed
to the inhibition of cystin import leading to glutathione depletion, as c steine which
can be formed rom the reduction of cystine is a rat -limiting precur or for glutathion
biosynthesis [11]. The r le xCT in promoting selenium ptake and selen protein ex-
pr sion suggested t us that Erastin may also function to disrupt the selenium-de endent
expr ssion f GPX4, which given the role of GPX4 in ferroptosis may greatly aff ct a cancer
cell’s sensitivity or resistanc t ferroptosis. xCT is thought to promot selenium entry
into a cell becau e som of the imported cystine is intracellularly reduced to cysteine and
exported, providing extracellular reduced thiol groups which allow selenite (SeO3) to be
reduced t sele ide to initiate the selenocysteine biosynthesis pathway (Figure 2a) [4,12].
We found that Erastin treatment in breast cancer cells diminished the levels of extracellular
thiols (Figure 2b), eliminated their selenite uptake (Figure 2c), and reduced expression of
the selenoprotein antioxidants GPX1 and GPX4 (Figure 2d,e), indicating that Erastin is
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disrupting xCT-mediated extracellular reduction which leads to selenium uptake and se-
lenoprotein production in these cells. These findings support the model for xCT function in
GPX4 expression which we previously proposed [4]: that xCT, by allowing cystine import
which is in turn reduced and exported to provide extracellular thiols, results in selenite
reduction and uptake, leading to production of selenoproteins such as GPX4. Erastin, by
inhibiting the cystine import function of xCT, hinders this process and the production of
GPX4. These doses of Erastin (3 or 6 µM) did not cause significant toxicity at the time point
for these experiments (Supplementary Figure S3a,b), indicating that cellular toxicity is not a
reason for reduced extracellular thiols, selenium uptake, and GPX expression. Furthermore,
we observed that Erastin did not decrease, and actually slightly increased, expression of
SLC3A2 and SLC7A11 subunits in these cells (Figure 2d,e), supporting that Erastin worked
through direct inhibition of xCT activity rather than impairing xCT subunit expression.
Collectively, these findings further support the role of xCT in driving the expression of
antiferroptotic agent GPX4, and suggest that inhibition of the selenocysteine biosynthesis
axis is an important consequence of xCT inhibition by Erastin.
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3.3. Breast Cancer Cells Have Increased Resistance against Cell Death Induced by Reactive Oxygen
Species Which Correlates with xCT Expression
The role of xCT in driving both glutathione production and the expression of glutathione-
utilizing enzymes such as GPX4 suggests that its expression may promote survival under
oxidative stress conditions for breast cancer cells that have elevation in xCT expression. We first
identified two TNBC cell lines, MDAMB231 and CAL-120, as having increased expression of
both SLC7A11 and SLC3A2, while two commonly used non-transformed mammary epithelial
lines, MCF10A and MCF12A, were found to express only SLC3A2 but not SLC7A11, and
are thus xCT-negative (Figure 3a,b). Next, we found that the breast cancer lines were highly
resistant to death induced by hydrogen peroxide (Figure 3c). This suggests that xCT-positive
breast cancer cells have a selective advantage against oxidative stress.
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r r lt t f r t t t iti r t r ll r i
i le els of both SLC7A1 and SLC3A2—Are able to drive GPX4 expression through the
selenocysteine biosynthesis pathway, and also are able to resist lipid prooxidant-induced
death. This is in line with the known function of both xCT and GPX4 in protecting against
ferroptosis in various cell stress states.
e next exa ined the sensitivity of these cancer and noncancer cells to prolonged
exposure to agents targeting the xCT and GPX4 anti-ferroptotic achinery, Erastin and
Rsl-3 (Figure 4a). Surprisingly, in contrast to their increased resistance against reactive
oxygen species, we found that MDAMB231 and CAL120 cells were hypersensitive to both
Erastin and Rsl-3 relative to the nontransformed lines. We observed that treatment of
Erastin, even in the absence of a prooxidant insult such as hydrogen peroxide, induced
a dramatic loss of cell viability (Figure 4b,c) and significant accumulation of lipid perox-
idation species (Figure 4d). The loss of viability induced by Erastin or Rsl-3 treatment
appeared to be caused by lipid peroxidation and ferroptosis, as they were rescued by the
lipid antioxidant/ferroptosis inhibitor ferrostatin-1 or α-tocopherol (Figure 4e,f). Thus,
while the TNBC cells had an augmented defense system mediated by xCT and GPX4
against oxidative stress (Figure 3c), they were paradoxically more dependent on these
pathways, compared to normal cells, to prevent ferroptosis. This suggests an “addiction
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scenario” that can be further explored in future studies for optimal therapeutic targeting in
breast cancer.
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4. Discussion
The expression of both SLC7A11 and SLC3A2 subunits can be a marker for xCT
function and selenoprotein production capacity of breast cancer cells. xCT consists of
two subunits, SLC7A11 and SLC3A2. High expression of either SLC7A11 and SLC3A2
has been previously reported in several tumor types. SLC7A11 is highly expressed in
many types of tumors such as acute myeloid leukemia, breast cancer, colorectal cancer,
hepatocellular carcinoma, glioma, etc., and its high expression is associated with poor
prognosis of patients with cancers [13,14]. SLC3A2 is highly expressed in breast cancer [15]
and osteosarcoma [16]. Especially, the expression of SLC7A11 alone has been utilized to
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evaluate the expression of xCT [17–22]. To our knowledge, there has not been an approach
to determine the expression of both SLC7A11 and SLC3A2 to evaluate the prognostic
value of xCT. However, we previously showed that depletion of any subunits makes xCT
nonfunctional [4], which means that confirming the expression of one subunit may not
represent the existence of functional xCT in cells. In addition, SLC3A2 also comprises
the heavy subunit of the large neutral amino acid transporter (LAT1) with a light subunit
protein encoded by the SLC7A5 gene [23] which indicates that SLC3A2 may be expressed
as a part of LAT1 complex in some cases. Thus, evaluating one subunit could not be an
accurate marker for functional xCT. In this study, the expression of both subunits was
evaluated side-by-side to evaluate a level of potentially functional xCT in breast normal
and cancer tissues. Some tumors expressed only one subunit and others expressed both
subunits which we defined as a xCT high tumor. The significantly elevated expression of
GPX4 in xCT-positive tumors versus their paired normal tissues, or versus xCT-negative
tumors, supports the notion that tumors expressing high levels of both subunits could be
an indicator for the existence of the functional xCT which leads to high selenium uptake
and upregulation of selenoproteins. However, this relationship between expression levels
of xCT subunits and selenoproteins should be validated with larger sets of paired samples
to further clarify the effect of the functional xCT on selenium uptake and its relationship
with the expression of various selenoproteins in tumor pathophysiology.
Erastin and xCT inhibitors as a strategy to inhibit selenium uptake and GPX4 pro-
duction in cancer cells. Erastin is currently being explored as a cancer therapy agent, in
large part due to its role in inducing ferroptosis. Sulfasalazine and sorafenib are other
compounds that have been similarly explored as xCT inhibitors, although they may have
wider effects and target profile compared to Erastin [24,25]. Modified compounds based
on Erastin with improved stability and/or bioavailability have also been developed [26].
Therefore, fully understanding the mechanism for Erastin and related compounds is of
importance in further developing these as a therapeutic strategy. Here we show that Erastin
drastically impairs extracellular thiol reduction, selenium uptake, and expression of the
selenoprotein GPX4. This finding is significant, as the current model of Erastin mode
of action only considers that of impairing glutathione biosynthesis. According to our
findings, impaired production of GPX4, a key enzyme implicated in ferroptosis preven-
tion which uses glutathione as substrate, is an additional important mechanism of action
for Erastin/xCT inhibitors, one that by itself could have ferroptosis triggering properties
even if glutathione production were to somehow be restored. A potential workaround
for cancer cells around impaired GPX4 production is that aside from the common dietary
selenium compound selenite, there are other independent routes by which selenium could
be obtained, in particular recycling of selenocysteine obtained from selenium carriers such
as SEPP1, or from selenomethionine, both of which would involve the action of seleno-
cysteine lyase (SCLY) in forming selenide from selenocysteine, prior to its conversion to
selenocysteinyl-tRNA. Thus, impairing this route of selenocysteinyl-tRNA formation in
conjunction with xCT inhibition could have even more potent effects, and the potential
functions of SCLY in cancer and ferroptosis should be explored in future studies.
‘Addiction’ of breast cancer cells to xCT/GPX4 anti-ferroptotic machinery. Conversely
to the known effect of xCT inhibitors such as Erastin sensitizing or triggering ferroptosis,
the increased expression or activity of xCT is implicated in the increased resistance of cancer
cells against insults that can trigger ferroptosis, such as hypoxia or chemotherapy [27–29].
Along similar lines, the role of selenium in producing antioxidant selenoproteins forms
the very basis of selenium being considered an antioxidant nutritional supplement [30,31].
Recently, selenocysteine delivered via synthetic peptide was shown to protect against
ferroptosis in a stroke model [32]. We also recently showed that CRISPR disruption
of selenocysteine biosynthesis machinery (SEPSECS, PSTK) hypersensitizes cancer cells
against the lipid prooxidant tert-butyl hydroxide (TBH) [4]. Therefore, it was not surprising
that the breast cancer lines MDAMB231 and CAL120, which have elevated expression
of both xCT subunits, have increased resistance against hydrogen peroxide compared to
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the nontransformed immortalized lines MCF10A and MCF12A, which are xCT-negative
(Figure 3). What was highly unexpected was that at the same time, MDAMB231 and
CAL120 are hypersensitive to the drugs which directly target the machinery that allowed
them to resist hydrogen peroxide, namely xCT (Erastin) and GPX4 (Rsl-3). This suggests a
scenario in which anti-ferroptotic machinery is upregulated in these cancer cells but at the
same time they are ‘addicted’ or highly dependent on this machinery even in the absence
of an insult such as hydrogen peroxide.
How are why are cancer lines addicted? One possibility involves selenide, which is
formed by xCT activity in the process of selenocysteine biosynthesis (which ultimately
results in GPX4 production). We have shown that the accumulation of hydrogen selenide
gas formed during selenocysteine biosynthesis is toxic to cancer cells by increasing ROS
levels [4]. As xCT-positive cancer cell lines are producing more selenide, they may be more
dependent on the end product GPX4 to neutralize selenide-induced oxidative stress. As a
second possibility, cancer cells might be more detrimental to GPX4 inhibition because they
have a higher level of polyunsaturated fatty acids (PUFAs). Basal-like breast cancer cell
lines are susceptible to ferroptosis due to the expression of acyl-CoA synthetase long-chain
family member 4 (ACSL4) which enriches cellular membranes with long polyunsaturated
fatty acids (PUFAs) [33]. Since ACSL4 is expressed higher in breast cancer compared to the
adjacent normal tissue [34], and PUFAs are targets of lipid peroxidation, cancer cells might
be more susceptible to lipid peroxidation and ferroptosis, thus GPX4 is more essential in
cancer cells. As a third possibility, as the xCT-positive cancer cells are expected to have
increased glutathione production and GPX4 expression, the resulting increased antioxidant
capacity may be accompanied by a reduced selective requirement for other anti-ferroptotic
or prosurvival signaling activities, meaning that when this xCT/GPX4-mediated protection
is removed, these cancer cells are vulnerable compared to ‘nonaddicted’ cells.
5. Therapeutic Implications and Concluding Thoughts
We have shown that cancer cells that overexpress both SLC7A11 and SLC3A2 are
the ones that should be considered xCT-positive, and that this pathway, through the
selenocysteine biosynthesis pathway mediated production of GPX4, impacts a cancer cell’s
sensitivity to various ferroptotic inducers. While future studies should delineate the exact
underlying mechanism, our finding that xCT positive cancer cells are simultaneously
resistant to lipid peroxidation insult yet hypersensitive to xCT or GPX4 inhibitors raises
important therapeutic implications. There are two classes of ferroptotis inducers: those
which directly trigger peroxidation such as hydrogen peroxide, and those that target a cell’s
defense against lipid peroxidation. Our results imply that in xCT positive cancers, the latter
is the desirable approach. xCT is widely reported to be upregulated in different subtypes of
cancers, and has been linked with oncogenic mutations such as Keap1 loss, and associated
with clinical parameters such as chemoresistance. Our findings provide a starting point
and rationale for targeting anti-ferroptotic machinery of cancer cells depending on their
xCT status, which can be further developed in future studies.
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